Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03978637 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03978637 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 23 participants.
The verdict
NCT03978637, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).
Interventions
- DRUG Itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-02-04 |
| Est. Completion | 2023-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03978637
The ClinicalTrials.gov registry entry for NCT03978637 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Itacitinib is the first listed.
NCT03978637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03978637 about?
NCT03978637 is a clinical study titled "Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).
What is the current status of trial NCT03978637?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2020-02-04. Estimated completion is 2023-10-13.
What interventions are being tested in trial NCT03978637?
The interventions under investigation include: Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03978637?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.